Bayer, Wins

Bayer Wins FDA Nod for First-in-Class Stroke Drug as Deutsche Bank Lifts Target to EUR 65

Published on 11/16/2026 at 07:11 | Editorial boerse-global.de
FDA clears Sunharbo as first factor XIa inhibitor; Deutsche Bank lifts Bayer target to EUR 65, Jefferies holds at EUR 48.50.
Bayer, Wins, FDA, Nod, First-in-Class, Stroke, Drug, Bank, Lifts, Target Illustration mit AI erstellt.

Bayer's pharmaceutical pipeline got its most tangible boost in years this week, with US regulators clearing Sunharbo for launch just as the company's quarterly figures prompted one major brokerage to raise its valuation on the stock.

The FDA approved asundexian under the Sunharbo brand for adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, to be used alongside antiplatelet therapy. According to Bayer, it is the first factor XIa inhibitor cleared anywhere in the world. Shipments were expected to begin between mid- and late November, the company said on 10 November.

Two Brokers, Two Verdicts

Deutsche Bank Research responded to the quarterly update by lifting its price target to EUR 65 from EUR 60, keeping a "Buy" rating. Analyst Virginie Boucher-Ferte pointed to higher earnings estimates following the results, raising her forecasts for earnings before interest, taxes, depreciation and amortisation as well as for earnings per share — adjustments that apply to 2027 and 2028.

Should investors sell immediately? Or is it worth buying Bayer?

Jefferies took a different view on the same day, maintaining "Hold" with a EUR 48.50 target. Analyst Michael Leuchten argued that the US approval of Sunharbo has substantially reduced the risk attached to Bayer's pharmaceutical pipeline, though the firm stopped short of recommending a higher valuation.

The shares finished Friday at EUR 56.66, up 0.2% on the session, after Bayer disclosed the US green light earlier in the week. dpa-AFX reported that Bayer stock remained in demand following the decision.

Guidance Raised on Pharma Strength

Bayer's third-quarter 2026 revenue reached EUR 10.1 billion, with EBITDA before special items of EUR 1.62 billion. Alongside the improved full-year outlook, the group raised its expectations for the adjusted operating result, the margin in its pharmaceuticals division and free cash flow. Media reports attributed the brighter profit forecast in large part to the stronger drug business.

A Missouri Jury Sides With Monsanto

Separately, the company notched a legal win. A jury in Missouri rejected claims brought by three plaintiffs against Bayer subsidiary Monsanto on 9 November, according to Reuters. The verdict covers only that individual case and does not determine the outcome of the pending global settlement.

Ad

Bayer Stock: New Analysis - 16 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYER | boerse | 70519398 |